Signaturefd LLC Has $37,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Signaturefd LLC lifted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 357.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,175 shares of the company’s stock after purchasing an additional 918 shares during the period. Signaturefd LLC’s holdings in Apellis Pharmaceuticals were worth $37,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after purchasing an additional 735,160 shares during the period. Braidwell LP boosted its stake in shares of Apellis Pharmaceuticals by 410.8% during the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock worth $90,130,000 after acquiring an additional 2,513,383 shares during the period. Jennison Associates LLC increased its holdings in shares of Apellis Pharmaceuticals by 51.6% during the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock worth $88,084,000 after acquiring an additional 939,289 shares during the last quarter. Geode Capital Management LLC raised its stake in Apellis Pharmaceuticals by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock valued at $52,229,000 after acquiring an additional 22,609 shares during the period. Finally, Cibc World Markets Corp acquired a new stake in Apellis Pharmaceuticals during the 4th quarter valued at $41,014,000. 96.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on APLS. The Goldman Sachs Group decreased their price objective on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. JPMorgan Chase & Co. upped their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Royal Bank of Canada decreased their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a research report on Monday, March 3rd. Finally, Wedbush dropped their price target on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $45.53.

Insider Activity

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 6,247 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $179,288.90. Following the sale, the chief executive officer now owns 307,415 shares in the company, valued at $8,822,810.50. This trade represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Caroline Baumal sold 2,816 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the sale, the insider now directly owns 55,560 shares in the company, valued at approximately $1,878,483.60. The trade was a 4.82 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,054 shares of company stock worth $1,952,719. Insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Trading Down 2.1 %

Shares of Apellis Pharmaceuticals stock opened at $23.76 on Wednesday. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 12-month low of $23.37 and a 12-month high of $59.91. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of -11.70 and a beta of 0.92. The firm’s 50-day moving average price is $27.37 and its two-hundred day moving average price is $29.78.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. During the same quarter last year, the business posted ($0.73) EPS. The firm’s revenue for the quarter was up 45.2% on a year-over-year basis. On average, analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).